Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:16 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 849 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Prospective Blood Draw Clear all

Conditions: Unintended Weight Loss
Interventions: GRAIL Galleri; Diagnostic Test
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 40 Years to 80 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Multiple Myeloma, Hodgkin Lymphoma, Non-hodgkin Lymphoma
Interventions: Plerixafor, Gcsf; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Intubation; Difficult, Respiration Disorders
Interventions: Dexmedetomidine; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 69 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: San Francisco, California

Conditions: COLIC, BILIARY TRACT DISEASES
Interventions: sublingual nitroglycerine; Drug
Lead sponsor: United States Naval Medical Center, San Diego; Federal
Eligibility: 18 Years to 60 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: San Diego, California

Conditions: Diabetes Mellitus, Type 2
Interventions: LY2963016, Lantus, OAMs; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 759 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 28
States / cities: Montgomery, Alabama • Brooksville, Florida • Fort Lauderdale, Florida + 25 more

Conditions: Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions: Continuous Glucose Monitoring System; Device
Lead sponsor: Senseonics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Escondido, California

Conditions: Locally Advanced Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
Interventions: Carboplatin, Cisplatin, Computed Tomography, Durvalumab, Etoposide, Image Guided Radiation Therapy, Nab-paclitaxel, Osimertinib, Paclitaxel, Pemetrexed, Positron Emission Tomography, Questionnaire Administration, Stereotactic Body Radiation Therapy; Drug · Procedure · Biological + 2 more
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 474 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2036
U.S. locations: 476
States / cities: Birmingham, Alabama • Daphne, Alabama • Fairhope, Alabama + 357 more

Conditions: Colorectal Neuroendocrine Tumor G1, Gastric Neuroendocrine Tumor G1, Neuroendocrine Neoplasm, Neuroendocrine Tumor, Neuroendocrine Tumor G2
Interventions: Bevacizumab, Laboratory Biomarker Analysis, Octreotide Acetate, Recombinant Interferon Alfa-2b; Biological · Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 427 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2027
U.S. locations: 493
States / cities: Mobile, Alabama • Fairbanks, Alaska • Fort Smith, Arkansas + 321 more

Conditions: Glioblastoma Multiforme, Glioblastoma, Glioma, Brain Tumor, Neoplasms, Neoplasms, Nerve Tissue
Interventions: NaviFUS System, Lumason, Bevacizumab; Device · Drug
Lead sponsor: NaviFUS Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Hematologic Disease, Blood Coagulation Disorders
Interventions: Recombinant Factor VIII (Kogenate, BAY 14-2222); Behavioral
Lead sponsor: Bayer; Industry
Eligibility: 14 Years to 29 Years · Male only
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 7
States / cities: Duarte, California • Denver, Colorado • Peoria, Illinois + 4 more

Conditions: Peripheral Vascular Disease, Hemorrhage
Interventions: EVICEL ™ Fibrin Sealant (Human); Biological
Lead sponsor: Ethicon, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 2
States / cities: Jacksonville, Florida

Conditions: Porphyria Cutanea Tarda
Interventions: Hydroxychloroquine, Phlebotomy; Drug · Procedure
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years to 100 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2021
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Chronic Obstructive Pulmonary Disease, HIV, Emphysema
Interventions: blood draw, questionnaires, Lung function testing, Six-Minute walk test, Quantitative CT scans, Nasal secretion and cell collection, Echocardiogram; Procedure · Radiation
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 80 Years
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Von Willebrand Disease
Interventions: Vonicog alfa, Antihemophilic Factor (Recombinant); Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: Up to 17 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 16
States / cities: Aurora, Colorado • Washington D.C., District of Columbia • Jacksonville, Florida + 12 more

Conditions: Peri-Implantitis, Bleeding of Subgingival Space
Interventions: Clinical measurements, Radiographic measurement, Dental prophylaxis or maintenance; Diagnostic Test · Procedure
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 80 Years
Enrollment: 164 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Renal Allograft Recipients
Interventions: Belatacept, Tacrolimus, Cyclosporine A, Mycophenolate Mofetil, Enteric Coated Mycophenolate Sodium, Corticosteroids; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2034
U.S. locations: 15
States / cities: Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 12 more

Conditions: Primary Ciliary Dyskinesia, Healthy
Interventions: Lung Function Testing, Phlebotomy, Allergy skin prick testing, Methacholine Challenge; Procedure
Lead sponsor: Indiana University; Other
Eligibility: 6 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Melanoma, Cutaneous Malignant, Mucosal Melanoma
Interventions: IMA203, nivolumab plus relatlimab, lifileucel, nivolumab, pembrolizumab, ipilimumab, Dacarbazine, temozolomide, paclitaxel, paclitaxel plus carboplatin, Albumin-Bound Paclitaxel; Biological · Drug
Lead sponsor: Immatics US, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 43
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 35 more

Conditions: Coronavirus Disease (COVID-19), SARS-CoV-2 Infection
Interventions: T-Detect™ SARS-CoV-2 Assay; Other
Lead sponsor: Adaptive Biotechnologies; Industry
Eligibility: 18 Years to 89 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Secaucus, New Jersey

Conditions: Age Related Macular Degeneration
Interventions: ranibizumab, dexamethasone and verteporfin, Ranibizumab; Drug
Lead sponsor: Bay Area Retina Associates; Other
Eligibility: 50 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 4
States / cities: Castro Valley, California • Walnut Creek, California • Riverdale, Georgia + 1 more

Conditions: Primary Immune Deficiency Disorder
Interventions: Bivigam, Other; Biological
Lead sponsor: ADMA Biologics, Inc.; Industry
Eligibility: Not listed
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 17
States / cities: Carpinteria, California • Walnut Creek, California • Centennial, Colorado + 12 more

Conditions: Anemia of End Stage Renal Disease
Interventions: Specimen collection; Other
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 3
States / cities: Louisville, Kentucky • Springfield, Massachusetts • Durham, North Carolina

Conditions: Chronic Graft vs. Host Disease, GVHD, cGVHD, Graft Versus Host Disease in Skin
Interventions: Axatilimab; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Lung Transplant, Post Lung Transplantation
Interventions: Blood Draw, Bronchoscopy; Procedure
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 884 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 4
States / cities: Los Angeles, California • Baltimore, Maryland • Durham, North Carolina + 1 more

Search by objective public record fields.

Unintentional Weight Loss and Cancer: A Prospective Trial of Patient-centered Weight Tracking Combined With GRAIL Galleri Testing to Improve Early Detection

Mozobil for Autologous Hematopoietic Stem Cell Transplantation

Use of Dexmedetomidine to Facilitate Extubation in Surgical ICU Patients Who Failed Previous Weaning Attempts

Treatment of Suspected Cholelithiasis With Nitroglycerin

A Study in Adults With Type 2 Diabetes

Gemini Study: A Prospective, Multicenter Evaluation of Performance and Safety of the Eversense Gemini System With Flash Glucose Measurement Feature

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)

Evaluation of the Reasons and Consequences of Bleeding in Late Teens and Early Adulthood Patients With Severe Hemophilia A

The Evicel Post-Authorization Surveillance Study

Hydroxychloroquine and Phlebotomy for Treating Porphyria Cutanea Tarda

Longitudinal Evaluation of HIV-associated Lung Disease Phenotypes

A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)

Incidence of Bleeding on Probing as an Indicator of Peri-Implant Disease Progression

A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications

Examining Bronchial Hyperresponsiveness in Primary Ciliary Dyskinesia

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

ImmuneSense™ COVID-19 Study

Triple Therapy - PDT Plus IVD and Intravitreal Ranibizumab Versus Lucentis Monotherapy to Treat Age-Related Macular Degeneration

A Study About Low Blood Pressure in Patients With Primary Immunodeficiency Disease Treated With Immune Globulin Products

Prospective Observational Study of Erythropoietin-Iron Interaction in Anemia of Renal Disease

Effects of Axatilimab on Skin in Chronic Graft-versus-Host Disease

CLAD Phenotype Specific Risk Factors and Mechanisms